Ani Pharma picks up generic player for a cool $210M, turbocharging its manufacturing and R&D wings
Contract manufacturing work has grown at a rapid clip the past year given demand caused in part by Covid-19. Big players are doubling down on …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
